Antimicrobial characteristics of quinupristin/dalfopristin (Synercid® at 30:70 ratio) compared to alternative ratios for in vitro testing

Diagnostic Microbiology and Infectious Disease

Volumn 27, Issue 4, 1997, Pages 129-138

  Jamjian, Christine ^a   Barrett, Mary S ^a   Jones, Ronald N ^a,b  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINDAMYCIN; DALFOPRISTIN; DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; VIRGINIAMYCIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; CONTROLLED STUDY; DRUG MIXTURE; ENTEROCOCCUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS; STREPTOCOCCUS;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MICROBIAL; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; HAEMOPHILUS INFLUENZAE; HUMANS; MICROBIAL SENSITIVITY TESTS; PASTEURELLA MULTOCIDA; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS; VIRGINIAMYCIN;

EID: 0030957170     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(97)00031-X     Document Type: Article

References (21)

1. Archer GL, Auger P, Doern GV, Ferraro MJ, Fuchs PC, Jorgensen JH, Low DE, Murray PR, Reller LB, Stratton CW, Wennersten CB, Moellering RC (1993) RP 59500, a new streptogramin highly active against recent isolates of North American staphylococci. Diagn Microbiol Infect Dis 16:223-226.
2. Aumercier M, Bouhallab S, Capmau ML, LeGoffic F (1992) RP 59500: A proposed mechanism for its bactericidal activity. J Antimicrob Chemother 30 (suppl A):9-14.
3. Barriere JC, Paris JM (1993) RP 59500 and related semisynthetic streptogramins. Drugs Future 18:845-883.
4. Barry AL, Fuchs PC (1995) In vitro activities of a streptogramin (RP 59500), three macrolides, and an azalide against four respiratory tract pathogens. Antimicrob Agents Chemother 39:238-248.
5. Chant C, Rybak MJ (1995) Quinupristin/dalfopristin (RP 59500): A new streptogramin antibiotic. Ann Pharmacother 29:1022-1027.
6. Collins LA, Malanoski GJ, Eliopoulos GM, Wennersten CB, Ferraro MJ, Moellering RC (1993) In vitro activity of RP 59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms. Antimicrob Agents Chemother 37:598-601.
7. Etienne SD, Montay G, LeLiboux A, Frydman A, Garaud JJ (1992) A phase I, double-blind, placebo-controlled study of the tolerance and pharmacokinetic behavior of RP 59500. J Antimicrob Chemother 30 (suppl. A):123-131.
8. Fantin B, Leclercq, Merle Y, Saint-Julien L, Veyrat C, Duval J, Carbon C (1995) Critical influence of resistance to streptogramin B-type antibiotics activity of RP 59500 (quinupristin/dalfopristin) in experimental endocarditis due to Staphylococcus aureus. Antimicrob Agents Chemother 39:400-405.
9. Pass RJ (1991) In vitro activity of RP 59500, a semisynthetic injectable pristinamycin, against staphylococci, streptococci, and enterococci. Antimicrob Agents Chemother 35: 553-559.
10. Freeman C, Robinson A, Cooper B, Mazens-Sullivan M, Quintiliani R, Nightingale C (1995) In vitro antimicrobial susceptibility of glycopeptide-resistant enterococci. Diagn Microbiol Infect Dis 21:47-50.
11. Gaillard C, VanContfort J, Montay G, Piffard D, LeLiboux A, Etienne S, Scheen A, Frydman A (1992) Disposition of the radiolabeled streptogramin RP 59500 in healthy male volunteers. In Program and Abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy (Anaheim, CA). Washington DC: American Society for Microbiology.
12. Goto S, Miyazaki S, Kaneko Y (1992) The in-vitro activity of RP 59500 against gram-positive cocci. J Antimicrob Chemother 30 (suppl. A):25-28.
13. Johnson CC, Slavoski L, Schwartz M, May P, Pitsakis PG, Shur AL, Levison ME (1995) In vitro activity of RP 59500 (quinupristin/dalfopristin) against antibiotic-resistant strains of Streptococcus pneumoniae and Enterococci. Diagn Microbiol Infect Dis 21:169-173.
14. Jones RN (1996) Medium and supplement effects on the antimicrobial activity of quinupristin/dalfopristin tested by agar dilution and Etest methods. Diagn Microbiol Infect Dis (in press).
15. Jones RN, Sader HS, Erwin ME, Anderson SC, The Enterococcus Study Group (1995) Emerging resistant enterococci among clinical isolates: I. Prevalence data from 97 medical center surveillance study in the United States. Diagn Microbiol Infect Dis 21:85-93.
16. Jorgensen JH, Elmeel ML, Liaci JA (1995) Activity of RP 59500 and its components, quinupristin and dalfopristin, against Haemophilus influenzae. In Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco CA). Washington, DC: American Society for Microbiology.
17. L'Heriteau F, Entenza JM, Lacassin F, Leport C, Glauser MP, Moreillon P (1995) RP 59500 prophylaxis of experimental endocarditis due to erythromycin-susceptible and -resistant isogenic pairs of viridans group streptococci. Antimicrob Agents Chemother 39:1425-1429.
18. National Committee for Clinical Laboratory Standards (NCCLS) (1993) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved Standard M7-A3. 3rd edition. Villanova, PA: NCCLS.
19. National Committee for Clinical Laboratory Standards (NCCLS) (1995) Performance standards for antimicrobial susceptibility testing. 5th Information supplement, M100-S5. Villanova, PA: NCCLS.
20. Nobel WC, Virani Z, Cree RGA (1992) Co-transfer of vancornycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microb Ltrs 93:195-198.
21. Verbist L, Verhaegen J (1992) Comparative in-vitro activity of RP 59500. J Antimicrob Chemother 30 (suppl. A):39-44.